Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
June 05, 2024 07:35 ET
|
Axsome Therapeutics, Inc.
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central...
Ollie’s Bargain Outlet Reports First Quarter Fiscal 2024 Financial Results
June 05, 2024 07:30 ET
|
Ollie's Bargain Outlet Holdings, Inc.
~ Comparable Store Sales increased 3.0% ~~ Earnings per Share increased 50.0% to $0.75 ~~ Adjusted Earnings per Share increased 49.0% to $0.73 ~~ Raising Fiscal Year Sales and Earnings Outlook ~ ...
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
June 05, 2024 07:30 ET
|
MiNK Therapeutics
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 07:30 ET
|
Passage Bio
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Ocular Therapeutix® to Host Investor Day on June 13, 2024
June 05, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD...
Ollie’s Bargain Outlet Announces Executive Promotions and Appointments as Part of Anticipated Leadership Succession
June 05, 2024 07:28 ET
|
Ollie's Bargain Outlet Holdings, Inc.
John Swygert to Transition to Executive Chairman in Early 2025 Eric van der Valk Promoted to President and Will Become CEO in Early 2025 Robert Helm Promoted to Executive Vice President Chris...
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
June 05, 2024 07:05 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
June 05, 2024 07:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research...
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 07:00 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2024 07:00 ET
|
G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)